Telix Pharmaceuticals (TLX) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Telix Pharmaceuticals (TLX) has outperformed Viking Therapeutics (VKTX) over the past year, gaining 7.5% versus a loss of 14.3%. Telix Pharmaceuticals is the larger company by market cap ($3.78 billion vs $3.61 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TLX | VKTX |
|---|---|---|
| Share price | $11.12 | $28.40 |
| Market cap | $3.78B | $3.61B |
| 1-day change | +0.99% | +2.42% |
| YTD return | +47.00% | -21.18% |
| 1-year return | +7.52% | -14.33% |
| 5-year return | — | +361.40% |
| P/E ratio (TTM) | 111.19 | — |
| EPS (TTM) | $0.10 | $-4.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $803.79M | $0 |
| Revenue growth (YoY) | +55.61% | — |
| Net income (latest FY) | $-7.13M | $-359.64M |
| Gross margin | 53.05% | — |
| Operating margin | 3.70% | — |
| Net margin | -0.89% | — |
| 52-week high | $13.11 | $43.15 |
| 52-week low | $6.28 | $25.77 |
| Distance from 52-week high | -15.19% | -34.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +83.65% | +233.49% |
| Average volume | 261.67K | 4.13M |
| Shares outstanding | 339.78M | 127.17M |
| Employees | 1,120 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLX has outperformed VKTX by 21.9 percentage points over the past year.
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
TLX vs VKTX FAQ
Which is bigger, Telix Pharmaceuticals or Viking Therapeutics?
Telix Pharmaceuticals (TLX) is larger, with a market capitalization of $3.78B compared with $3.61B for Viking Therapeutics (VKTX).
Which stock has performed better over the past year, TLX or VKTX?
TLX returned +7.52% over the past 12 months, compared with -14.33% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are Telix Pharmaceuticals and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.